Patients with chronic ITP
| Patient no.* . | Age, y . | Sex . | Platelet count, ×109/L . | Antiplatelet antibodies† . | Major previous drugs . | Bleeding symptoms . | |
|---|---|---|---|---|---|---|---|
| Anti-GPIIb/IIIa . | Anti-GPIb/IX . | ||||||
| 1 | 19 | F | 23 | − | + | None | EC |
| 2 | 32 | M | 68 | + | − | Pred | EC, EP |
| 3 | 40 | F | 11 | − | − | Dex VCR | PT |
| 4 | 36 | F | 21 | − | + | Pred VCR Splenectomy | PT, EC |
| 5 | 39 | M | 13 | − | − | None | None |
| 6 | 42 | M | 55 | − | − | Pred CSA | PT |
| 7 | 27 | F | 25 | + | − | Dex Danazol | EP |
| 8 | 34 | M | 10 | − | − | None | GUH |
| 9 | 27 | F | 5 | + | + | None | PT, EP |
| 10 | 16 | F | 20 | + | − | Pred VCR Splenectomy | GH |
| 11 | 17 | M | 38 | − | − | None | PT, EC |
| 12 | 22 | F | 2 | − | + | None | EC |
| 13 | 36 | F | 30 | + | + | None | EP |
| 14 | 50 | F | 49 | + | − | Dex | PT |
| 15 | 50 | F | 30 | + | + | Pred | PT, EP |
| 16 | 55 | F | 3 | + | + | Pred VCR | EP |
| 17 | 49 | M | 8.77 | + | − | None | None |
| 18 | 42 | F | 49 | + | − | None | EP, EC |
| 19 | 16 | M | 19 | + | − | Pred | EP |
| 20 | 41 | F | 33 | − | + | Pred | PT, GH |
| 21 | 16 | M | 37 | − | + | Pred VCR | PT |
| 22 | 46 | F | 8 | − | − | None | PT, EC |
| 23 | 20 | M | 50 | − | − | None | PT, EC |
| 24 | 17 | M | 11 | − | − | Pred | EP |
| 25 | 33 | M | 9 | − | − | Pred VCR | PT, GUH |
| 26 | 27 | F | 18 | − | − | None | None |
| 27 | 21 | M | 53 | − | − | IVIG | None |
| 28 | 32 | F | 19 | − | + | Pred VCR | PT |
| 29 | 27 | M | 9 | − | + | None | EP |
| 30 | 38 | M | 41 | + | + | Dex | PT, GUH |
| 31 | 23 | F | 13 | + | − | Pred CSA | EC, EP |
| 32 | 25 | M | 62 | − | − | Dex | PT, EC |
| 33 | 34 | F | 15 | + | + | None | EC |
| 34 | 39 | F | 23 | − | + | None | None |
| 35 | 17 | M | 38.1 | − | − | Pred Danazol | PT, EP |
| 36 | 63 | F | 7.61 | − | − | Pred | EP |
| 37 | 42 | F | 10 | − | − | None | EP, EC |
| 38 | 37 | F | 17 | + | + | None | EC |
| 39 | 24 | M | 55 | − | − | Pred | PT |
| 40 | 26 | F | 42 | + | − | None | PT, EC |
| 41 | 70 | M | 10 | + | − | None | PT, EC |
| 42 | 29 | M | 2 | + | − | None | EC, EP |
| 43 | 25 | F | 14 | − | + | Pred | EP |
| 44 | 19 | F | 2 | − | − | None | EP |
| 45 | 61 | F | 6 | − | − | None | PT |
| 46 | 29 | M | 4 | − | − | Pred | GUH |
| 47 | 47 | F | 66 | − | − | Dex | PT, GH |
| 48 | 53 | M | 31 | + | + | None | PT |
| 49 | 36 | F | 50 | + | − | Pred | PT, EP |
| Patient no.* . | Age, y . | Sex . | Platelet count, ×109/L . | Antiplatelet antibodies† . | Major previous drugs . | Bleeding symptoms . | |
|---|---|---|---|---|---|---|---|
| Anti-GPIIb/IIIa . | Anti-GPIb/IX . | ||||||
| 1 | 19 | F | 23 | − | + | None | EC |
| 2 | 32 | M | 68 | + | − | Pred | EC, EP |
| 3 | 40 | F | 11 | − | − | Dex VCR | PT |
| 4 | 36 | F | 21 | − | + | Pred VCR Splenectomy | PT, EC |
| 5 | 39 | M | 13 | − | − | None | None |
| 6 | 42 | M | 55 | − | − | Pred CSA | PT |
| 7 | 27 | F | 25 | + | − | Dex Danazol | EP |
| 8 | 34 | M | 10 | − | − | None | GUH |
| 9 | 27 | F | 5 | + | + | None | PT, EP |
| 10 | 16 | F | 20 | + | − | Pred VCR Splenectomy | GH |
| 11 | 17 | M | 38 | − | − | None | PT, EC |
| 12 | 22 | F | 2 | − | + | None | EC |
| 13 | 36 | F | 30 | + | + | None | EP |
| 14 | 50 | F | 49 | + | − | Dex | PT |
| 15 | 50 | F | 30 | + | + | Pred | PT, EP |
| 16 | 55 | F | 3 | + | + | Pred VCR | EP |
| 17 | 49 | M | 8.77 | + | − | None | None |
| 18 | 42 | F | 49 | + | − | None | EP, EC |
| 19 | 16 | M | 19 | + | − | Pred | EP |
| 20 | 41 | F | 33 | − | + | Pred | PT, GH |
| 21 | 16 | M | 37 | − | + | Pred VCR | PT |
| 22 | 46 | F | 8 | − | − | None | PT, EC |
| 23 | 20 | M | 50 | − | − | None | PT, EC |
| 24 | 17 | M | 11 | − | − | Pred | EP |
| 25 | 33 | M | 9 | − | − | Pred VCR | PT, GUH |
| 26 | 27 | F | 18 | − | − | None | None |
| 27 | 21 | M | 53 | − | − | IVIG | None |
| 28 | 32 | F | 19 | − | + | Pred VCR | PT |
| 29 | 27 | M | 9 | − | + | None | EP |
| 30 | 38 | M | 41 | + | + | Dex | PT, GUH |
| 31 | 23 | F | 13 | + | − | Pred CSA | EC, EP |
| 32 | 25 | M | 62 | − | − | Dex | PT, EC |
| 33 | 34 | F | 15 | + | + | None | EC |
| 34 | 39 | F | 23 | − | + | None | None |
| 35 | 17 | M | 38.1 | − | − | Pred Danazol | PT, EP |
| 36 | 63 | F | 7.61 | − | − | Pred | EP |
| 37 | 42 | F | 10 | − | − | None | EP, EC |
| 38 | 37 | F | 17 | + | + | None | EC |
| 39 | 24 | M | 55 | − | − | Pred | PT |
| 40 | 26 | F | 42 | + | − | None | PT, EC |
| 41 | 70 | M | 10 | + | − | None | PT, EC |
| 42 | 29 | M | 2 | + | − | None | EC, EP |
| 43 | 25 | F | 14 | − | + | Pred | EP |
| 44 | 19 | F | 2 | − | − | None | EP |
| 45 | 61 | F | 6 | − | − | None | PT |
| 46 | 29 | M | 4 | − | − | Pred | GUH |
| 47 | 47 | F | 66 | − | − | Dex | PT, GH |
| 48 | 53 | M | 31 | + | + | None | PT |
| 49 | 36 | F | 50 | + | − | Pred | PT, EP |
EC indicates ecchymoses; Pred, prednisone; EP, epistaxis; Dex, dexamethasone; VCR, vincristine; PT, petechiae; CSA, cyclosporine; GUH, genitourinary hemorrhage; GH, gingival hemorrhage; and IVIG, intravenous γ-globulin.
Plasma of patients 1 to 26 increased megakaryocyte production (group A); plasma of patients 27 to 40 suppressed megakaryocyte production (group B); and plasma of patients 41 to 49 did not affect megakaryocyte production (group C).
Antiplatelet antibodies were assayed by modified monoclonal antibody-specific immobilization of platelet antigens.